India's Apollo Hospitals extends gains as analysts upbeat on growth prospects
** Shares of Apollo Hospitals APLH.NS up 2.4% at 6,675 rupees
** Nuvama hiked PT to 7,500 rupees from 7,065 rupees, keeps "buy" rating; says APLH's guidance on 500-550 store openings in FY25 to drive 20% growth in online pharmacy
** ICICI Securities hikes PT to 6,215 rupees from 6,100 rupees, keeps "hold" rating; says hospital occupancies will likely risein next two quarters
** Motilal Oswal raised PT to Street high of 7,940 rupees on Wednesday,keeps "buy" rating
** Sees superior execution across segments, including on-track regulatory approvals for greenfield hospital project, commissioning of acquired hospitals
** At least 15 brokerages covering the stock raised PT post strong results on Tuesday - LSEG data
** Stock gained 3.4% in the previous session
** Indian markets remained closed on Thursday for holiday
** On Friday, stock is among top five percentage gainers on the Nifty 50 index .NSEI, which is up 1.4% .BO
Reporting by Manvi Pant in Bengaluru
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
